C4 Therapeutics Inc (CCCC) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for C4 Therapeutics Inc (US:CCCC), trading at 3.66. In 2025, C4 Therapeutics Inc generated $35.95 Million in revenue and -$99.30 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for C4 Therapeutics Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 3.66
- Recent Revenue (2025): $35.95 Million
- Free Cash Flow (2025): -$99.30 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.